Cellectis announced that the FDA has granted Orphan Drug Designation, or ODD, to Cellectis’ CLLS52, an Investigational Medicinal Product used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Cellectis Gains FDA Orphan Drug Status for ALL Therapy
- FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
- CLLS Earnings this Week: How Will it Perform?
- Cellectis Gains FDA Designations for Leukemia Therapy
- FDA grants Cellectis’ UCART22 ODD and RPDD status for ALL treatment